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Idiopathic inflammatory myopathies: pathogenic
mechanisms of muscle weakness
Sree Rayavarapu1,2, William Coley1, Travis B Kinder1,2 and Kanneboyina Nagaraju1,2*
Abstract
Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown
etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement
of other organ systems. It is generally believed that the autoimmune response (autoreactive lymphocytes and
autoantibodies) to skeletal muscle-derived antigens is responsible for the muscle fiber damage and muscle
weakness in this group of disorders. Therefore, most of the current therapeutic strategies are directed at either
suppressing or modifying immune cell activity. Recent studies have indicated that the underlying mechanisms that
mediate muscle damage and dysfunction are multiple and complex. Emerging evidence indicates that not only
autoimmune responses but also innate immune and non-immune metabolic pathways contribute to disease
pathogenesis. However, the relative contributions of each of these mechanisms to disease pathogenesis are
currently unknown. Here we discuss some of these complex pathways, their inter-relationships and their relation to
muscle damage in myositis. Understanding the relative contributions of each of these pathways to disease
pathogenesis would help us to identify suitable drug targets to alleviate muscle damage and also improve muscle
weakness and quality of life for patients suffering from these debilitating muscle diseases.
Keywords: Adaptive immune, Autophagy, Cytokines, Endoplasmic reticulum stress, Innate immune, Myositis,
Skeletal muscle, TLRs
Review
Idiopathic inflammatory myopathies (IIMs) include poly-
myositis (PM), dermatomyositis (DM) and sporadic in-
clusion body myositis (sIBM). The clinical features of
these diseases include muscle weakness, fatigue and ele-
vated muscle enzymes in serum, and their histological
characteristics include mononuclear cell infiltration and
myofiber degeneration. Immunological features include
autoantibodies and autoreactive lymphocytes, with un-
usual over-expression of major histocompatibility complex
(MHC) class I molecules on the surface of the affected
myofibers. MHC molecules present processed non-self
and self-antigenic peptides to T-lymphocytes and mediate
immune response. The relative contribution of the auto-
immune component to myositis pathogenesis is not yet
known. Recent data suggest that innate immune activation
and metabolic defects occur in the myositis muscle, sug-
gesting a role for these pathways in disease pathogenesis
[1-3]. Thus, the emerging paradigm indicates that not only
innate and adaptive immune mechanisms but also in-
trinsic defects in skeletal muscle contribute to muscle
weakness and damage in myositis. The muscle micro-
environment is complex, and we propose that active inter-
actions occur between innate, adaptive, metabolic and
homeostatic pathways in muscle in these diseases.
Innate immune mechanisms
Innate immunity, also known as native immunity, is
considered the early line of host defense. The innate
immune system includes physical barriers (epithelial sur-
faces), phagocytic cells (neutrophils, macrophages, eosi-
nophils, etc.), natural killer (NK) cells, the complement
system, and cytokines. Innate immune cells primarily de-
tect pathogen-derived antigen structures with common
patterns, but not fine differences, through Toll-like re-
ceptors (TLRs) and nucleotide-binding oligomeriza-
tion domain (NOD)-like receptors (NLRs), to initiate
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pro-inflammatory responses. We discuss TLRs, NLR-
inflammasomes, NF-kB, and cytokines in the context
of muscle inflammation below. All the information dis-
cussed in this section is summarized in Figure 1.
TLR signaling in skeletal muscle
TLRs are the trans-membrane receptors expressed on
immune and non-immune cells that recognize patho-
gens as well as self-molecules. Altogether, 13 TLRs have
been identified in mice and humans. All TLRs, except
TLR-3, signal via myeloid differentiation response gene
88 (MyD88), the central adaptor protein, and induce ac-
tivation of the nuclear factor-kB (NF-kB) pathway, the
master controller of inflammation. TLR-3 signals via Toll
interleukin (IL)-1 receptor domain-containing adaptor
inducing IFN-γ (TRIF) and activates the NF-kB pathway
or type I interferons (IFNs) [1,2,14]. TLRs recognize pat-
terns in microorganisms termed as pathogen-associated
molecular patterns (PAMPs) and endogenous ligands ter-
med as damage associated molecular patterns (DAMPs),
and initiate immune signaling [15,16]. PAMPs are asso-
ciated with infectious agents (e.g., bacteria, fungi and
viruses) whereas DAMPs are host-encoded molecules
released during tissue injury, necrosis and cell death.
DAMPs include nucleic acids (RNA, DNA), cytosolic heat
shock proteins and nuclear high mobility group box pro-
tein 1 (HMGB1), and extracellular matrix proteins such as
fibrinogen and fibronectin [5,6,17]. DAMPs have been
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Figure 1 Innate immune mechanisms of muscle damage in myositis. Skeletal muscle undergoes continuous injury and repair in response to
a variety of physiological (exercise) and pathological (infection) insults and releases damage-associated molecular patterns (DAMPs) from dead
and damaged cells (Step 1). DAMPs initiate innate immune signaling by binding to surface or endogenous TLRs on various cells including
skeletal muscle fiber, infiltrating macrophages (Mϕ), myeloid dendritic cells (mDCs), plasmacytoid DCs (pDCs), capillaries, and other cell types such
as fibroblasts (Step 2) [4-6]. This innate signaling through TLR and other innate immune receptors induces the secretion of pro-inflammatory
cytokines and chemokines [e.g., Type 1 interferons (IFN-α, IFN-β), TNF-α, IL-1, IL-12 and IFN-γ] into the microenvironment (Step 3). These cytokines
and DAMPs bind to their respective receptors on muscle and capillaries [e.g., tumor necrosis factor receptor (TNFR), IL-1 receptor (IL-1R)] and exert
downstream effects (Step 4) [7-10]. Cytokines and/or chemokines directly cause damage to capillaries and hypoxia in the affected muscle.
Cytokines such as TNF-α can directly induce cell death of muscle cells, while NF-kB is known to block MyoD and inhibit formation of the new
muscle fibers [11-13]. Thus this pathway not only effectively enhances the death of existing muscle fibers but also inhibits formation of new
muscle fibers leading to the loss of skeletal muscle mass and weakness in these disorders.
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shown to induce stimulation of TLRs, resulting in im-
mune activation and the release of cytokines, resulting in
a self-sustaining autoinflammatory response that con-
tributes to chronic inflammation in the affected tissue
[18-21].
Excessive physical activity and strenuous exercise in
normal individuals leads to modest elevations in serum
muscle enzymes such as creatine kinase (CK), whereas
myositis patients generally show a significant increase in
CK, suggesting that skeletal muscle leakiness and da-
mage occur in this disease. It is likely that some DAMPs
leak from the injured skeletal muscle and engage their
receptors on both skeletal muscle and immune cells,
thereby perpetuating the inflammatory process. In fact,
muscle biopsies of myositis patients show a significantly
increased expression of TLR-2, TLR-3, TLR-4, and TLR-
9 in the skeletal muscle and infiltrating cells as well
as the enhanced expression of cytokines such as IFN-γ,
IL-4, IL-17, TNF-α, IL-6 and type 1 IFNs. These findings
suggest that TLR receptors are engaged in the milieu of
affected muscle and that the downstream genes are acti-
vated [7-9]. Further, IFN-β and IFN-γ are shown to en-
hance MHC class I expression on immature muscle
precursors, suggesting that these cells may be one of the
sources of local type 1 IFNs and that the regenerating fi-
bers are potential targets of immune attack in myositis
muscle [22].
More recently, one study has independently validated
the enhanced expression of TLR-2, -4, and −9 along with
MyD88 mRNA transcripts, as well as enhanced protein
levels in all subtypes of inflammatory myopathies [10].
The evidence for activation of TLR-4, MyD88, and the
NF-κB pathway is also shown in a myosin-induced ex-
perimental autoimmune myositis (EAM) mouse model
[23]. An enhanced expression of transcripts such as
IFN-γ, IL-12p40, and IL-17 along with the expression of
the co-stimulatory molecules CD80 and CD86 in the in-
flammatory milieu of the affected muscle suggests the
link between innate and adaptive immune systems in the
muscle microenvironment [10].
Recognition of DAMPs that activate the TLR pathway
in myositis muscle is slowly emerging. For example, the
histidyl-tRNA-synthetase (HRS) protein has long been
associated with myositis, since it was identified as the
antigen of the myositis-specific autoantibody Jo-1. Pre-
vious studies indicated that cleaved HRS serves as a che-
mokine by binding to CCR5 and facilitates immune cell
infiltration into muscle [24]. More recent studies indi-
cate that the N-terminal portion of the HRS protein
binds to TLRs, and immunization with HRS peptides in-
duces both autoantibody formation and immunoglobulin
class switching in mice. A loss of TLR-4 inhibits class
switching, and a loss of TRIF inhibits both class switching
and autoantibody secretion [25]. The exact mechanisms
by which HRS cleavage and release from muscle cells oc-
curs is unclear, but there is evidence that HRS-expressing
immature muscle cells express high levels of MHC class I
and therefore likely become targets of cytotoxic T-cells
and granzyme B-mediated cleavage of the HRS an-
tigen [26].
Another well-characterized DAMP that is involved in
myositis pathogenesis is high mobility group box protein
1 (HMGB1). High expression of HMGB1 was detected
not only in the cytoplasm of muscle, infiltrating cells
and endothelial cells, but also in the interstitial space in
myositis muscle suggesting its potential to engage TLRs
in this milieu [4]. Exposure of HMGB1 to muscle fibers
induced irreversible decrease in calcium release from the
sarcoplasmic reticulum during fatigue induced by re-
peated tetanic contractions [27]. A recent study reported
that HMGB1 induced muscle fatigue occurs via the
TLR-4 pathway in muscle and that the HMGB1-TLR-4
pathway plays a role in the pathogenesis of myositis pa-
tients [4].
Taken together, these studies clearly suggest that TLRs,
acting through MyD88-dependent and/or independent
mechanisms, induce pro-inflammatory signals in myo-
pathic muscle. It is likely that new advances in this field
would identify additional novel DAMPs in myositis mus-
cle. Blocking DAMP induced MyD88 dependent and in-
dependent TLR pathways using chemical and genetic
methods may provide additional insights into these mech-
anisms. Although there are substantial gaps in our know-
ledge of the relationship between myositis and TLRs, and
their stimulation by endogenous DAMPs, the accumulat-
ing evidence suggests that the TLRs are the connecting
link that mediates interactions between innate and adap-
tive responses and in turn activates NF-kB signaling cas-
cades in myositis.
NF-kB and NLR-inflammasome activation in skeletal muscle
The NF-kB pathway is one of the predominant regula-
tors of a variety of essential biological processes, includ-
ing inflammation. In myositis both immune and skeletal
muscle cells modulate inflammation via the NF-kB path-
way. NF-kB is a ubiquitous transcription factor com-
posed of a heterodimer with two subunits, p65 (Rel A)/
c-Rel/Rel B and p50. NF-kB is kept sequestered in an in-
active form in the cytoplasm through an interaction with
its specific inhibitor IkBα. When a stimulus is received,
the upstream IkB kinase (IKK) phosphorylates IkBα,
leading to its proteosomal degradation. Free NF-kB is
then translocated to the nucleus, where it regulates the
expression of several pro-inflammatory genes, including
TNF-α and IL-1β. We have previously demonstrated
that unusual overexpression of MHC class I on the
muscle fibers of myositis muscle can also cause the acti-
vation of NF-kB, including the induction of ER stress
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response pathways [27]. Further evidence suggests that
downstream NF-kB target genes such as intercellular ad-
hesion molecules (ICAM) and MCP-1 are also highly
up-regulated in myositis muscle. Several groups have in-
dependently validated NF-kB activation in inflammatory
myopathies and its role in modulating the immune res-
ponse, myogenesis and muscle repair [11-13,28].
NLR-inflammasomes are intracellular multi-protein
complexes formed by the adaptor molecule apoptosis-
associated speck-like protein with caspase recruiting
domain (ASC), caspase-1, and the members of the NLR
family such as NLRP1, NLRP3 and NLRC4. NLR-inflam-
masomes are also activated by PAMPs/DAMPs and result
in secretion of the pro-inflammatory cytokines [29,30]. Al-
though the process is not yet completely understood, the
general consensus is that inflammasomes are activated
through three signaling pathways: 1) potassium efflux, 2)
generation of reactive oxygen species, and 3) production
of cathepsin B [31]. More recently, our group has shown
that normal primary skeletal muscle cells are capable of
secreting IL-1β in response to combined treatment with
TLR-4 ligand, lipopolysaccharide and P2X7 receptor
agonist, ATP, suggesting that not only immune cells but
also muscle cells can actively participate in inflammasome
formation implicating skeletal muscle cells in perpetuating
a pro-inflammatory environment [32].
The inflammasome pathway is connected to the TLR
signaling pathway. TLR-2/4 signaling results in the synthe-
sis of pro-IL-1β, and inflammasomes process pro-IL-1β
into mature IL-1β; signaling by released extracellular ATP
via P2X7 receptors (DAMP signaling) facilitates the secre-
tion of mature IL-1β from the skeletal muscle cells [32].
Another recent study has characterized the mechanism of
IL-1β secretion following respiratory syncytial virus (RSV)
infection of airways [33]. This study underscored the re-
quirement for the (TLR-2)/MyD88/NF-κB pathway prior
to the activation of the inflammasomes and subsequent
IL-1β release in the affected tissue [33]. In sum, these
findings suggest a possible cross-talk between TLRs and
inflammasome pathways. In myositis, the activation of in-
flammasomes and the subsequent release of cytokines in
affected muscle have not yet been investigated; however,
enhanced expression of both TLRs and IL-1α and IL-1β in
areas surrounded by inflammatory cells suggest that TLR-
inflammasome pathway is active in myositis muscle [34].
Therefore, it is possible that the cytokines released from
the activation of inflammasome pathways can stimu-
late innate and adaptive immune cells and further
augment the secretion of either pro-inflammatory or
anti-inflammatory cytokines.
Cytokines and chemokines in skeletal muscle
Cytokines are produced by a wide variety of cells and
regulate immune cell activation and infiltration in affected
tissues. The most predominantly reported cytokines in
myositis include pro-inflammatory cytokines such as IL-
1α, IL-1β, TNF-α and transforming growth factor (TGF)-β
[34-39]. IL-1α was predominantly expressed in capillary
endothelial cells of PM, DM and sIBM muscle biopsies
suggesting a prominent role for endothelial cells in myo-
sitis pathology [34,35]. Furthermore, IL-1α was suggested
to play a role in myofibrillar protein break down and
muscle regeneration; however, these claims are yet to be
proven [36]. The pathogenic role of TNF-α in myositis
muscle was not completely understood; however, it has
been hypothesized to attract immune cells by enhancing
transendothelial cell trafficking in affected muscle [37]. In
addition, TNF-α has been hypothesized to activate im-
mune cells and induce MHC class I expression in the
myositis muscle. TGF-β was proposed to play a pro-
fibrotic role based on the correlation between its expres-
sion and connective tissue proliferation in DM muscle
[39]. A plethora of studies have also reported the expres-
sion of additional cytokines and chemokines in myopathic
tissues [40-50] (Table 1).
Even though a majority of the reports suggest that cy-
tokines have a pro-inflammatory role in myositis muscle,
one recent study reported a protective role for some
cytokines. This study reported enhanced expression of
neurotrophin receptor p75NTR on the muscle fibers of
DM, PM and sIBM patients [52]. p75NTR binds to vari-
ous neurotrophin-like cytokines such as NGF, BDNF,
NTF3 or NTF4, and protects muscle cells against IL-1β
induced cell death. Taken together, these studies indicate
that cytokines and chemokines have different roles in
the affected skeletal muscle.
Adaptive immune mechanisms
Adaptive immunity to self-antigens is induced in auto-
immune diseases. This arm of immunity predominantly
includes autoreactive lymphocytes and autoantibodies.
Initial reports have indicated that there are differences
in the lymphocyte subsets seen in PM, DM and sIBM;
however, recent studies have indicated that those dif-
ferences are not clear-cut and that T-cells (CD4, CD8),
B-cells, macrophages, and DCs are present in all inflam-
matory myopathies. All the information discussed in this
section is summarized in Figure 2.
T-cells and CTL-cell-mediated injury
T-cells are involved in cell-mediated immune responses
within the adaptive immune system. These cells express
surface receptors (T-cell receptors; TCR) that recognize
peptide fragments of foreign proteins when presented on
the MHC molecules of antigen-presenting cells. Func-
tional subsets of T-cells include CD4+ T helper cells
(which recognize MHC class II-presenting peptides) and
CD8+ cytotoxic T-cells (which recognize MHC class
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I-presenting peptides). The role of CD4+ and CD8+
T-cells in inflammatory myopathies has been recognized;
however, their precise roles in the pathogenesis of myositis
are not completely understood. In the pathology of DM,
CD4+ T-cells are thought to play a major role; in contrast,
CD8+ T-cells seem to be the predominant actors in PM
[59,60]. CD8+ T-cells infiltrating myositis muscle have
been shown to express perforin-1 and granzyme-B en-
zymes, indicating that they have a cytotoxic effect on the
affected muscle (Figure 2) [58]. Recent studies demon-
strate the presence of CD28null T-cells, Th17 cells, and T-
regulatory cells in the muscle of PM and DM patients
[53,56,57] (Figure 2). The CD28null T-cells arise as a
result of a chronic inflammatory stimulus (such as in-
fection from virus) and are generally long-lived and
pro-inflammatory in nature. Likewise Th17 cells produce
IL-17 and IL-22. IL-22 has both tissue protection and pro-
inflammatory properties. Contribution of Th17 cells to in-
flammatory process in autoimmune diseases, such as
rheumatoid arthritis, is well delineated. Regulatory T-cells,
which express CD25, reduce inflammation and tissue
damage by inhibiting the function of antigen presenting
cells and T-effector cells. Even though the presence of dif-
ferent T-cell subpopulations in myositis muscle has been
well documented, their precise role in muscle pathology is
not yet clear.
B-cells and autoantibodies
B-cells that are derived from bone marrow migrate to
secondary lymphoid organs to elicit antigen specific
humoral immune response. B-cells and terminally differ-
entiated plasma cells have also been reported not only in
PM and DM but also in sIBM, indicating their role in
the pathogenesis of these diseases [61]. More recent re-
ports indicating an up-regulation of B-cell activating fac-
tor (BAFF) have also suggested that a local maturation
of B-cells to antibody-producing plasma cells may occur
in myositis muscle [61,62]. Despite the presence of
lymphoid aggregates, it is highly unlikely that B-cell ma-
turation occurs in the muscle; rather, these B-cells may
serve an antigen-presenting function.
Presence of myositis-specific antibodies against auto-
antigens such as histidyl-tRNA synthetase (anti-Jo-1)
and chromodomain-helicase DNA-binding proteins
(anti-Mi-2) has been well established in myositis patients;
more than half of all patients show autoantibodies. Several
different autoantibodies have been reported in different
myopathies [3,63-81] (Table 2). The majority of antibodies
reported are directed against ubiquitous cytoplasmic or
nuclear components involved in critical cellular regulatory
processes and the role of autoantibodies in mediating
muscle damage and injury is uncertain in myositis. How-
ever, autoantibodies are extremely useful for diagnosing
and classifying myositis patients and for predicting disease
course and therapeutic outcomes. For more information
on myositis autoantibodies, readers are advised to consult
the reviews [82,83].
Dendritic cells connect the innate and adaptive arms of the
immune system
There is clear evidence that innate and adaptive immune
cytokines influence each other. For instance, IL-18 sti-
mulates the secretion of IFN-γ and TNF-α via a Th1-
mediated response [84,85]. Similarly, IL-1β binds to
IL-1 receptor on dendritic cells and produces IL-23 via
a Th17-mediated response, and IL-33 binds to IL-1
receptor-related protein (ST2) and enhances the secre-
tion of IL-10 and IL-13 through Th2-mediated responses
[86]. IL-33 also induces the secretion of IL-13, IL-10 and
TGF-β by stimulating mast cells and T-reg cells [86].
These interactions through cytokines highlight that in-
nate and adaptive immune processes are interrelated
Table 1 Some of the important cytokines/chemokines reported in inflammatory myopathies
Cytokines/Chemokines Potential role References
IL-1α/IL1-β Pro-inflammatory and probably myofibrillar protein break down [34-36]
TNF-α Chemo-attractant [37]
TGF-β Pro-fibrotic [39]
IL-17 IL-6 production and HLA class I in muscle cells [40,41]
IL-151 T-cell activation, development of NK cells and NK-T-cells [51]
Type 1 interferons (IFN-α, IFN-β) Enhance type 1 interferon inducible transcripts (ISG15, MX1, IFIT3 and IRF7) [42-44]
Leukotriene B4 Chemo-attractant [45]
Macrophage inflammatory proteins (1α, 1β) Contribute to ongoing muscle inflammation [46]
RANTES2 Chemo-attractant [46]
Resistin/Adipocyte secreted factor Pro-inflammatory, probably involved in metabolic dysregulation [47-49]
TWEAK3 Impairs muscle differentiation and myogenesis [50]
1IL-15 and IL-6 are also called myokines.
2RANTES: Regulated on activation, normally T expressed and secreted.
3TWEAK: Tumor necrosis factor like weak inducer of apoptosis.
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and studies to understand their role in muscle disease
pathogenesis are imminent.
DCs are bone marrow-derived immune cells that
connect innate and adaptive immune systems. DCs are
considered professional antigen-presenting cells, and
their main function is to prime and activate naïve
T-lymphocytes. Immature DCs express CD1a and blood
dendritic cell antigen 2 (BDCA2) surface markers, where-
as mature DCs express DC-LAMP, CD83 and fascin
surface markers. We have previously shown that DC-
LAMP-positive dendritic cells are highly enriched in peri-
vascular inflammatory sites in juvenile and adult DM
patients, along with molecules that facilitate dendritic cell
transmigration and reverse transmigration (CD142 and
CD31) [87]. Both immature and mature DCs have been
found to be present in DM and PM biopsies [88,89].
Recent studies have reported that myeloid DCs may regu-
late type I IFN-mediated induction of cytokines and
chemokines in DM muscle, indicating an association bet-
ween DCs and type I IFN signatures in myositis muscle
[90]. More recently, plasmacytoid DCs (pDCs) have also
been implicated in myositis pathology. pDCs are innate
immune cells with a plasma-cell morphology that express
CD4 or the myeloid-cell markers MHC class II, CD36,
CD68 and CD123 [91]. pDCs characteristically produce
type I IFNs and other chemokines in response to virus-
derived nucleic acids, via the activation of endosomal
TLR-7 and TLR-9 pathways (Figure 1). They may serve as
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Figure 2 Adaptive immune mechanisms of muscle damage in myositis. DAMP signaling through TLRs in the innate immune cells activates
various antigen-presenting cells (APC) in the muscle (shown in Figure 1). These APCs activate CD4 T-cells via MHC class I and CD8 T-cells initiate
autoantigen specific T-cell responses (Step 1) [26]. Activated CD4+ T-cells differentiate into T-helper (Th)-17 (TGF-β), Th2 (IL-4), and Th1(IL-12)
effector T-cells in the presence of respective cytokines, and in turn produce discrete sets of cytokines that affect a variety of cell types (Step 2)
[53]. Th1 cells through IFN-γ generate M1 macrophages, which secrete TNF-α, IL-6 and IL-1, and damage cells. Th2 cells, through IL-4, TGFβ and
IL-10, generate M2 macrophages that are known to help tissue repair and remodeling in the affected tissues [54,55]. Th2 cells also help stimulate
B-cell maturation and differentiation into plasma cells that produce autoantibodies and further initiate complement mediated damage to
capillaries and induce hypoxia (Step 3). Cytotoxic CD28−/− T-cells and regulatory T-cells (Tregs) reduce inflammation and tissue damage by
inhibiting the function of antigen presenting cells and T-effector cells [56,57]. It is also known that activated CD8 T-cells differentiate into
cytotoxic T-cells (CTL) and exert cytotoxic effects on the affected muscle through secretion of perforin-1 and granzyme-B enzymes (Step 4) [58].
Thus the myositis muscle microenvironment is complex, with both tissue repair and tissue-damaging mechanisms in play at all times. The relative
ratios of these pathways determine the disease severity and progression.
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an essential link between innate and adaptive immune
mechanisms through the secretion of type 1 IFNs and
other cytokines [92,93].
Macrophages are tissue-based phagocytic cells derived
from peripheral monocytes. They carry out a multitude
of functions, including antigen presentation to T-cells
and scavenging of necrotic tissues via phagocytosis. Dif-
ferent types of macrophages in the muscle clearly influ-
ence the type of the adaptive immune response (e.g., Th1
or Th2). Distinct subpopulations of macrophages have
been described; M1 macrophages, in association with
Th1 cells, produce pro-inflammatory mediators and are
involved in the phagocytosis of microorganisms and
neoplastic cells. M2 macrophages are Th2-associated
and are involved in tissue remodeling/repair and the
production of anti-inflammatory molecules. Depending
on their stage of activation, macrophages exhibit dif-
ferent surface markers; MIF-related protein (MRP) 14
and 27E10 represent early-stage markers; 25F9 is a late-
activation marker. Infiltration of macrophages into myo-
sitis tissues and the presence of CD163 positive (M1)
macrophages are described in myositis muscle [4,54,55].
Characterization of macrophage subtypes in PM and DM
muscle indicated that they express both early, MRP14 and
27E10 (M1 macrophage) and late activation 25F9 (M2
macrophage) and inflammatory markers such as iNOS
and TGF-β [54,55]. These studies indicate that both M1
and M2 macrophages exist in the myositis muscle and
their relative proportions may vary depending on the stage
of the disease process. Therefore, interactions between
innate immune cells/cytokines and lymphocytes appear
to be dynamic and alter with the type and stage of the
disease.
Non-immune mechanisms
Because of the presence of immune cells, it is generally
thought that myofiber damage is the consequence of an
immune process to muscle derived antigen. However,
several observations suggest the involvement of non-
immune mechanisms in myositis pathology: 1) the lack
of a correlation between the degree of inflammation and
skeletal muscle weakness; 2) the lack of a response to
potent immunosuppresants by some myositis patients;
and 3) the lack of any amelioration of clinical disease
even after complete removal of inflammatory infiltrates
from the myositis muscle. Here we describe the litera-
ture related to skeletal muscle homeostasis and metabo-
lism that supports a role for non-immune mechanisms
in myositis pathology. Hereditary IBM (hIBM) is a an
autosomal recessive muscle disorder tied to a muta-
tion in the UDP-N-acetylglucosamine 2-epimerase/
N-acetylmannosamine kinase (GNE) that codes for a
rate-limiting enzyme in the sialic acid biosynthetic
pathway. Pathogenesis of hIBM is considered non-
inflammatory and is not discussed in this review. All
the information discussed in this section is summa-
rized in Figure 3.
Metabolic/energy pathways in skeletal muscle
Mitochondrial energy-related metabolic pathways play a
prominent role in skeletal muscle because of the high
demand for energy in these cells. Mitochondria can
regulate various signaling pathways via the production
of ATP, NADH and reactive oxygen species. Emerging
evidence indicates a probable dysregulation of mito-
chondrial energy pathways in inflammatory muscle di-
seases [99,105]. Studies have reported abnormal succinic
Table 2 Some of the important autoantibodies reported in inflammatory myopathies
Autoantibodies Disease Association References
Anti-tRNA synthetases1 (Anti-Jo; against
histidyl tRNA synthetase)
More common in PM than DM Interstitial lung disease [63-65]
Anti-chromodomain helicase DNA binding
proteins (anti-Mi2)
DM Cutaneous lesions [3,66,67]
Anti-MDA5/Anti-CADM-140 DM Mucocutaneous lesions; severe lung disease
minimal muscle involvement
[68-70]
Anti-TIF1γ2 DM Malignancy [71-73]
Anti-nuclear matrix protein (NXP)-2/anti-MJ Mostly juvenile DM Joint contractures; calcinosis [74]
Anti-SAE3 DM Skin and muscle manifestations [75]
Anti-signal recognition particle NM, PM Degenerating and regenerating muscle fibers
and possible cardiac involvement
[76-79]
Anti-HMG-CoA reductase4 Statin associated myopathy Treatment with cholesterol lowering drugs [80,81]
PM Polymyositis, DM Dermatomyositis, NM Necrotizing myopathy.
1Additional antisynthetase antibodies found in myositis are targeted against threonyl-tRNA synthetase (PL-7); alanyl-tRNA synthetase (PL-12); isoleucyl-tRNA
synthetase (OJ); glycyl-tRNA synthetase (EJ); asparaginyl-tRNA synthetase (KS).
2TIF1γ: Transcription intermediary factor 1γ.
3SAE: Small ubiquitin like modifier activating enzyme.
4HMG-CoA reductase: 3-hydroxy-3-methylglutaryl-coenzymeA reductase.
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dehydrogenase and cytochrome c oxidase (COX) activities
in DM muscle and observed that these abnormalities are
more pronounced in damaged, atrophic perifascicular fi-
bers [100,101]. Pro-inflammatory cytokines (specifically
TNF-α) have also been shown to affect muscle metabo-
lism, leading to weakness. TNF-α acts via the TNFR1 re-
ceptor subtype and reduces the specific force generated by
muscles. This reduction in force is attributed to increased
cytosolic oxidant activity and decreased myofibrillar func-
tion and specific force without altering calcium regulation
or other aspects of myofibrillar mechanics [102]. These
findings indicate a potentially detrimental effect of pro-
inflammatory cytokines on skeletal muscle and mitochon-
drial energy metabolic pathways.
One of the often-overlooked features of myositis is the
apparent acquisition of metabolic defects within the
skeletal muscle. These defects are generally described
as deficiencies of glycolytic enzymes and other proteins
found preferentially in fast-twitch fibers. One of the
oldest proposed metabolic defects in inflammatory my-
opathies is an acquired deficiency of a rate-limiting
enzyme, AMPD1, in purine nucleotide cycle [106,107].
Recently, our group demonstrated that AMPD1 mRNA,
protein expression and enzyme activity are significantly
reduced in the MHC class I mouse model of myositis, as
compared to healthy littermate mice [103]. A cause-and-
effect relationship between AMPD1 and muscle weak-
ness has been demonstrated by reducing the levels of
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Figure 3 Non-immune mechanisms of muscle damage and weakness. MHC class I overexpression on myofibers make muscle susceptible
for CD8 T-cell mediated cytotoxicity as well as susceptible to endoplasmic reticulum stress-induced cell death. MHC class I accumulation in
endoplasmic reticulum induces stress responses (unfolded protein response and endoplasmic reticulum overload response (EOR)) [27,94-98].
Induction of EOR activates downstream NF-kB pathway leading to pro-inflammatory cytokine production and reduction in new muscle formation
by inhibiting MyoD. It also induces cell death mechanisms via the activation of caspases 12, 3 and 7 as well as calpain pathways (Step A) [27].
Innate cytokines, mitochondrial energy-related metabolic pathways, and purine nucleotide pathways are interconnected in myositis muscle. For
instance, IL-1 reduces the production of nitric oxide (NO) and causes mitochondrial dysfunction by affecting NADH reductase and succinate CoQ
[99-102]. Likewise, unknown cytokines reduce expression of rate-limiting enzymes of the purine nucleotide cycle and of AMPD1 in skeletal
muscle. This acquired deficiency of APMD1 causes muscle weakness and fatigue in myositis (Step B) [103]. Activation of TRAIL forms autophagosomes
and induces autophagy (Step C) [104]. TLR signaling leads to inflammasome activation, IL-1 secretion and pyroapoptosis in the affected muscle. There
are active interactions between autophagy, ER stress, and inflammasome and purine nucleotide pathways. Even though all these pathways are
interconnected, we have represented them as linear pathways in this illustration for easier understanding. Thus, several non-immune and metabolic
pathways directly and indirectly contribute to muscle weakness and damage in myositis.
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AMPD1 in normal mice. The most novel observation
was that a significant loss of AMPD1 enzyme activity
and muscle strength occurs prior to the appearance of
infiltrating lymphocytes. These results suggest that the
metabolic deficiencies seen in myositis are independent
of the action of infiltrating autoreactive lymphocytes.
At this time, it is unclear what factors/cytokines regu-
late AMPD1 levels in skeletal muscle. Evaluation of the
AMPD1 promoter has indicated that cytokines are likely
to modulate AMPD1 expression in skeletal muscle. For
example, the cytokine IL-15 has the potential to serve as
a link between inflammation and muscle metabolism.
IL-15 was first described as a weak ligand for the IL-2
receptor complex, and as such is capable of stimulating
T-cell proliferation, among other immunomodulatory ef-
fects. Recent work has shown that IL-15 signaling affects
the formation of fast-twitch fibers in mice; in the
absence of the IL-15 receptor, muscle fibers appear to
convert from fast-twitch to slow-twitch fibers [108]. Fur-
thermore, strong staining for IL-15 has been detected in
myoblasts but not in mature muscle fibers [51]. These
results are particularly interesting, considering the previ-
ously mentioned evidence that immature fibers may be-
come a focal point of inflammation as a result of the
secretion of IL-15, and the subsequent loss of these
IL-15-positive fibers might explain the observed shift to-
ward slow-twitch fibers in myositis patients [51]. Even
though the precise role of these metabolic pathways
in the myofiber damage seen in myositis is not yet
clear, it is possible that innate TLR pathways and pro-
inflammatory cytokines regulate these mechanisms.
Endoplasmic reticulum stress
A non-immune role for MHC class I has been reported
in myositis. Muscle-specific overexpression of MHC
class I causes the myositis phenotype in mouse skeletal
muscle [109]. Studies have reported an induction of
endoplasmic reticulum stress as the result of an un-
usual up-regulation of MHC class I in myositis muscle
[27,94-96]. More recently, studies to understand the role
of endoplasmic reticulum stress in muscle pathology
reported the expression of classical markers of endoplas-
mic reticulum stress (GRP78, GRP94 and calreticulin) in
the affected skeletal muscle of both mice and humans
[27,97,98,110]. A recent study has reported the presence
of stress response proteins and heat shock proteins
(Hsp) in IIM patients [111]. More specifically, the authors
have examined the effects of chronic inflammation on the
distribution of Hsp families 70 and 90 in muscle biopsies.
Their results have indicated that regenerating, atrophic
and vacuolated muscle fibers show an upregulation of
both protein families, whereas infiltrating cells show en-
hanced levels of Hsp 90 family proteins. These results in-
dicate a differential expression of stress proteins in muscle
cells and immune cells. Thus, the authors suggest that
chaperones play multifaceted roles in inflammatory mus-
cle tissue. For more detail and a comprehensive discussion
of the relationship between endoplasmic reticulum stress
and muscle pathology, readers are referred to a recent re-
view on this subject [112].
Autophagy
Autophagy is the lysosomal degradation of a cell’s own
proteins or organelles. Evidence of autophagy is often
seen in PM and sIBM. Muscle biopsies from humans
with sIBM and PM with mitochondrial pathology display
the autophagosome marker LC3-II [99]. However, the
precise role of autophagy in muscle diseases is contro-
versial. It is likely that autophagy has both beneficial and
adverse effects, depending on the cell stage and dis-
ease process involved. The in vitro inhibition of lyso-
somal autophagic enzymes has been reported to activate
γ-secretase, which cleaves amyloid precursor protein to
release the self-aggregating amyloid-β fragment [113]. We
have demonstrated that TNF-related apoptosis-inducing
ligand (TRAIL) and markers of autophagy are up-
regulated in myositis muscle fibers. Incubation of skeletal
muscle cells with TRAIL induces IκB degradation and
NF-κB activation, suggesting that it mediates the activa-
tion of NF-κB as well as autophagic cell death in myo-
pathic muscle [104]. Another recent report has also
indicated that TNF-α induces macroautophagy and subse-
quent expression of MHC class II on muscle cells [114].
More importantly, blockade of TNF-α with monoclonal
antibodies has been shown to improve C protein-induced
myositis (CIM) in mice, suggesting a probable role for au-
tophagic pathways in myositis pathology [115]. In addi-
tion, immunomodulators such as fibrinogen and HMGB1
are correlated with the progression of myositis and are be-
lieved to induce autophagy by signaling through TLR-4,
indicating a probable association with innate immune
mechanisms [116]. Even though these findings indicate
that autophagy plays a role in myofiber damage in myo-
sitis, further studies are needed to show how and when
these autophagic mechanisms are triggered in the affected
muscle.
Conclusions
The emerging picture indicates that myositis is a com-
plex disease with multiple pathogenic pathways simul-
taneously contributing to muscle damage and weakness.
Among these, the most prominent are the innate, adap-
tive immune and metabolic pathways. Innate immune
pathways link the adaptive and metabolic arms of the
disease processes. Additional new pathways and the pre-
cise interactions between these components are likely to
be described in the future, and the relative contribution
of each of these pathways to pathogenesis remains to be
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elucidated. However, it is clear that targeting the adap-
tive immune system alone is unlikely to provide signifi-
cant relief from muscle weakness and damage in this
group of disorders. New therapies are needed to modu-
late both the innate immune and metabolic components
of the disease processes in order to obtain significant
amelioration of the myositis phenotype.
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